Literature DB >> 8304975

Oxidative activity of primaquine metabolites on rat erythrocytes in vitro and in vivo.

J Vásquez-Vivar1, O Augusto.   

Abstract

The oxidative activities of primaquine [6-methoxy-8-(4-amino-1-methylbutylamino)quinoline] and its metabolites, the quinone-imine derivatives of 5-hydroxyprimaquine [5-hydroxy-6-methoxy-8-(4-amino-1-methylbutylamino)quinoline] and 5-hydroxydemethylprimaquine [5-hydroxy-6-demethyl-8-(4-amino-1-methylbutylamino)quinoline], 6-methoxy-8-amino quinoline and hydrogen peroxide, were studied on rat erythrocytes in vitro and in vivo. In both cases, the most effective metabolites in oxidizing hemoglobin and depleting non-protein sulfhydryl groups from erythrocytes were the quinone-imine derivatives of the ring-hydroxylated metabolites, 5-hydroxyprimaquine and 5-hydroxydemethyl-primaquine. The latter quinone-imines were shown by light absorption spectroscopy and oxygen consumption studies to be able to oxidize purified rat hemoglobin to methemoglobin but to be unable to react directly with reduced glutathione. In agreement with these results, no radical adduct was detected by electron paramagnetic resonance spectroscopy in incubations of rat erythrocytes with the quinone-imines and the spin-trap 5,5-dimethyl-1-pyrroline-N-oxide; metabolite-derived free radicals were detected instead. Taken together, the results suggest that 5-hydroxyprimaquine and 5-hydroxydemethylprimaquine are important metabolites in the expression of primaquine hemotoxicity, in contrast to 6-methoxy-8-aminoquinoline. Additionally, the results indicate that hydrogen peroxide is the ultimate oxidant formed from the ring-hydroxylated metabolites by redox-cycling of the corresponding quinone-imine derivatives both in vitro and in vivo.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8304975     DOI: 10.1016/0006-2952(94)90022-1

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  16 in total

1.  Differential cytochrome P450 2D metabolism alters tafenoquine pharmacokinetics.

Authors:  Chau Vuong; Lisa H Xie; Brittney M J Potter; Jing Zhang; Ping Zhang; Dehui Duan; Christina K Nolan; Richard J Sciotti; Victor E Zottig; N P Dhammika Nanayakkara; Babu L Tekwani; Larry A Walker; Philip L Smith; Robert M Paris; Lisa T Read; Qigui Li; Brandon S Pybus; Jason C Sousa; Gregory A Reichard; Bryan Smith; Sean R Marcsisin
Journal:  Antimicrob Agents Chemother       Date:  2015-04-13       Impact factor: 5.191

2.  Tafenoquine: A Step toward Malaria Elimination.

Authors:  Kuan-Yi Lu; Emily R Derbyshire
Journal:  Biochemistry       Date:  2020-02-24       Impact factor: 3.162

3.  Methemoglobin reductase activity and in vitro sensitivity towards oxidant induced methemoglobinemia in swiss mice and beagle dogs erythrocytes.

Authors:  S Srivastava; A S Alhomida; N J Siddiqi; S K Puri; V C Pandey
Journal:  Mol Cell Biochem       Date:  2002-03       Impact factor: 3.396

4.  DFT study on the radical anions formed by primaquine and its derivatives.

Authors:  Haining Liu; Larry A Walker; Robert J Doerksen
Journal:  Chem Res Toxicol       Date:  2011-07-07       Impact factor: 3.739

5.  Differential CYP 2D6 metabolism alters primaquine pharmacokinetics.

Authors:  Brittney M J Potter; Lisa H Xie; Chau Vuong; Jing Zhang; Ping Zhang; Dehui Duan; Thu-Lan T Luong; H M T Bandara Herath; N P Dhammika Nanayakkara; Babu L Tekwani; Larry A Walker; Christina K Nolan; Richard J Sciotti; Victor E Zottig; Philip L Smith; Robert M Paris; Lisa T Read; Qigui Li; Brandon S Pybus; Jason C Sousa; Gregory A Reichard; Sean R Marcsisin
Journal:  Antimicrob Agents Chemother       Date:  2015-02-02       Impact factor: 5.191

6.  Effect of antimalarial drug primaquine and its derivatives on the ionization potential of hemoglobin: A QM/MM study.

Authors:  Haining Liu; Yuanqing Ding; Larry A Walker; Robert J Doerksen
Journal:  Medchemcomm       Date:  2013-08-01       Impact factor: 3.597

7.  Tafenoquine and NPC-1161B require CYP 2D metabolism for anti-malarial activity: implications for the 8-aminoquinoline class of anti-malarial compounds.

Authors:  Sean R Marcsisin; Jason C Sousa; Gregory A Reichard; Diana Caridha; Qiang Zeng; Norma Roncal; Ronan McNulty; Julio Careagabarja; Richard J Sciotti; Jason W Bennett; Victor E Zottig; Gregory Deye; Qigui Li; Lisa Read; Mark Hickman; N P Dhammika Nanayakkara; Larry A Walker; Bryan Smith; Victor Melendez; Brandon S Pybus
Journal:  Malar J       Date:  2014-01-03       Impact factor: 2.979

8.  Hydroxylated derivatives of NPC1161: theoretical insights into their potential toxicity and the feasibility and regioselectivity of their formation.

Authors:  Yuanqing Ding; Haining Liu; N P Dhammika Nanayakkara; Ikhlas A Khan; Babu L Tekwani; Larry A Walker; Robert J Doerksen
Journal:  J Phys Chem A       Date:  2014-07-11       Impact factor: 2.781

9.  Computational Study on the Effect of Exocyclic Substituents on the Ionization Potential of Primaquine: Insights into the Design of Primaquine-Based Antimalarial Drugs with Less Methemoglobin Generation.

Authors:  Haining Liu; Yuanqing Ding; Larry A Walker; Robert J Doerksen
Journal:  Chem Res Toxicol       Date:  2015-01-27       Impact factor: 3.739

10.  Pre-clinical evaluation of CYP 2D6 dependent drug-drug interactions between primaquine and SSRI/SNRI antidepressants.

Authors:  Xiannu Jin; Brittney Potter; Thu-Lan Luong; Jennifer Nelson; Chau Vuong; Corttney Potter; Lisa Xie; Jing Zhang; Ping Zhang; Jason Sousa; Qigui Li; Brandon S Pybus; Mara Kreishman-Deitrick; Mark Hickman; Philip L Smith; Robert Paris; Gregory Reichard; Sean R Marcsisin
Journal:  Malar J       Date:  2016-05-17       Impact factor: 2.979

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.